Medicaid clients and members rate Prime’s performance

We asked, and they told us how we’re doing. And it’s very good news.

September 24, 2019
The Medicaid team at Prime is committed to serving this important audience. We want to know how we’re doing. So, every year, we send clients and members a satisfaction survey. For two straight years, Medicaid clients scored Prime at 100 percent overall client satisfaction. Medicaid members have also returned very high satisfaction scores.

When our clients are satisfied, so are we

Our Medicaid clients specifically showed high satisfaction with Prime’s reporting, flexibility and our client engagement/account teams. Prime scored 100 percent in these areas:

  • Resolving problems in a timely manner
  • Member marketing communication and collateral (electronic and print)
  • Delivery of training or information on new products and services
  • Network pricing and strategy

Prime is pleased to report these high client satisfaction and high member satisfaction scores. Our most recent survey showed that 92 percent of our clients’ Medicaid members reported being “satisfied” or “very satisfied” with their prescription drug plan. For Prime, this is extremely good news, because we always put members first. It’s part of our purpose. It’s how we work with Blue Plans to make health care better.

Medicaid programming is an essential part of what a health plan offers its community. Diversity of a population’s needs, as well as regulatory oversight, demand a unique market-specific focus. Prime understands that this unique market requires a dedicated team. Prime’s Medicaid team really understands this market. We collaborate with our clients to find solutions that balance low cost and quality outcomes. This approach drives our success, providing value that benefits our clients and members.

Related news

Stories

July 22, 2024

Introducing the latest issue of our medical and pharmacy benefit management report

The summer 2024 issue of the Magellan Rx Report provides insights on the industry’s most groundbreaking managed care solutions in some of the most complex areas of health care

Stories

July 18, 2024

Specialty drug trend forecasted to drop for employer groups, clinical experts say

Introduction of Humira® and Stelara® biosimilars contribute to continued decline in the autoimmune – anti-inflammatory trend

Stories

July 16, 2024

Prime/Magellan Rx earns top score on the Disability Equality Index

For the second consecutive year, Prime Therapeutics/Magellan Rx Management received a score of 100 on the Disability Equality Index®, which benchmarks disability workplace inclusion